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Aim To validate a deep-learning (DL) algorithm for automated quantification of
prostate cancer on positron emission tomography/computed tomography (PET/
CT) and explore the potential of PET/CT measurements as prognostic biomarkers.
Material and methods Training of the DL-algorithm regarding prostate volume was
performed on manually segmented CT images in 100 patients. Validation of the
DL-algorithm was carried out in 45 patients with biopsy-proven hormone-na€ıve
prostate cancer. The automated measurements of prostate volume were compared
with manual measurements made independently by two observers. PET/CT mea-
surements of tumour burden based on volume and SUV of abnormal voxels were
calculated automatically. Voxels in the co-registered 18F-choline PET images above
a standardized uptake value (SUV) of 265, and corresponding to the prostate as
defined by the automated segmentation in the CT images, were defined as abnor-
mal. Validation of abnormal voxels was performed by manual segmentation of
radiotracer uptake. Agreement between algorithm and observers regarding pros-
tate volume was analysed by Sørensen-Dice index (SDI). Associations between
automatically based PET/CT biomarkers and age, prostate-specific antigen (PSA),
Gleason score as well as overall survival were evaluated by a univariate Cox
regression model.
Results The SDI between the automated and the manual volume segmentations was
078 and 079, respectively. Automated PET/CT measures reflecting total lesion
uptake and the relation between volume of abnormal voxels and total prostate
volume were significantly associated with overall survival (P = 002), whereas
age, PSA, and Gleason score were not.
Conclusion Automated PET/CT biomarkers showed good agreement to manual mea-
surements and were significantly associated with overall survival.
Introduction
High sensitivity, functionality, and quantification are hall-
marks of molecular imaging, including positron emission
tomography/computer tomography (PET/CT). However,
these abilities are not used to the extent they deserve in
cancer. Prostate-specific antigen (PSA) is non-specific (Bell
et al., 2014), the Gleason score is subjective with moderate
reproducibility (Sadik et al., 2008; Ozkan et al., 2016), and
bone metastases are late occurring events (Hoilund-Carlsen
et al., 2018). Thus, precise characterization of prostate can-
cer patients at the time of diagnosis is currently suboptimal
and reliable markers for individualized assessment are
needed.
Clin Physiol Funct Imaging (2020) 40, pp106–113 doi: 10.1111/cpf.12611
106 © 2019 The Authors. Clinical Physiology and Functional Imaging published by John Wiley & Sons Ltd on behalf of Scandinavian Society of Clinical
Physiology and Nuclear Medicine 40, 2, 106–113
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
In recent years, deep-learning (DL) has become the method
of choice for automated image analysis (Lakhani et al., 2018).
Radiology studies have reported on application of deep learn-
ing in different organs (Lehman et al., 2018; Nam et al., 2018;
Tao et al., 2019). Still, the prognostic role of that application
remains undefined and further investigation is needed.
Since automated quantitative PET/CT assessments are lack-
ing, imaging biomarkers are still not routinely used. Deep
learning in prostatic malignancies has previously been applied
in magnetic resonance imaging (MRI) (Wang et al., 2017;
Reda et al., 2018), whereas maximum standardized uptake
value (SUVmax) by 18F-FDG PET/CT appears to be of rele-
vance in predicting overall survival in metastasizing prostate
cancer (Jadvar et al., 2013).
Accordingly, the primary aim of this retrospective study is
to evaluate a novel three-dimensional deep learning-based
technique on PET/CT images for automated assessment of
cancer in the prostate gland and its agreement with manual
assessment. The secondary aim was to investigate the associa-
tion between automatically based estimates of prostate cancer





A deep learning algorithm was trained to segment the prostate
gland on CT scans using manual segmentation in 100 consec-
utive patients, who were selected from Sahlgrenska’s Univer-
sity Hospital, Gothenburg. These patients had a mean age of
56 years (range 21–85) and had undergone PET/CT scan
examination, between October 2008 and December 2010 for
colorectal (n = 22), lung (n = 17), lymphoma (n = 15),
head-and-neck (n = 14) or other known or suspected tumours
(n = 32). All examinations were pseudonymized before the
digital processing of their examinations. Thereafter, the algo-
rithm was applied in a validation group.
Validation group
The patients of the validation group were derived from a prior
study on staging of prostate cancer by PET/CT (Poulsen et al.,
2014). Inclusion criteria for that study were as follows:
biopsy-proven prostate cancer, whole-body bone scintigraphy
showing ≥1 bone metastases, ability to undergo MRI and
safely await androgen deprivation until all study scans were
completed. Exclusion criteria were as follows: ongoing or
prior androgen deprivation, pain or suspicion of medullar
compression due to bone metastases. All patients gave oral
and written informed consent. Out of 50 patients in the origi-
nal study, five with missing PET/CT were not included, leav-
ing 45 patients, with median age 73 years (range 53–92), for
analysis. Patients were recruited between May 2009 and
March 2012. At inclusion the median PSA was 83 ng/ml
(range 4–5740), Gleason score was 2–6 in six patients, seven
in 17, 8–10 in 21 patients and not available in one patient.
Thirty-three patients in the validation group died during fol-
low-up. Their median survival time was 25 years (range 03–
76) compared with 78 years (range 61–88) in the 12 sur-
viving patients. Clinical information and other data were col-
lected from the local medical records up until 12 March
2018.
Ethical approval for both groups was obtained from the
Ethics Committee at Gothenburg University (295-08) and the
Regional Ethics Review Boards in Sweden (2016/103) and
Denmark (3-3013-1692/1).
Imaging
Training data were obtained using an integrated PET/CT scan-
ner (Siemens Biograph 64 Truepoint, Gothenburg, Sweden).
A low-dose CT scan (64-slice helical, 120 kV, 30 mAs) was
performed from the base of the skull to mid-thigh. The CT
slice thickness was 5 mm. PET images were not used in the
training group.
Subjects in the validation group were scanned with PET/
CT (Discovery VCT, GE Healthcare, Odense, Denmark)
approximately 60 min after administration of 4 MBq/kg of
Table 1 Comparison between the automated and the manual PET/CT measurements (n = 43).
PET/CT measurements [Mean (95% confidence interval)]
DL-based Nuclear medicine physician Radiologist
SUVmaxa 86 (73–10) 78 (68–88) 88 (75–10)
SUVmeanb 41 (36–45) 44 (4–48) 39 (35–43)
VOLUME (ml)c 31 (247–374) 22 (148–286) 40 (31–482)
FRACTION (%)d 43 (36–495) – 59 (472–714)
TLUe 138 (1064–1705) 110 (73–146) 168 (1254–211)
aMaximal SUV within the prostate gland.
bAverage SUV for voxels with SUV > 265.
cVolume of prostate gland voxels with SUV > 265.
dFraction of VOLUME related to the whole volume of the prostate gland.
eProduct SUVmean 9 VOLUME reflecting the total lesion uptake.
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18F-choline following a 6-h fast. A contrast-enhanced CT
scan (64-slice helical, 120 kV, ‘smart mA’ maximum
400 mA) was obtained from base of the skull to mid-thigh
with a slice thickness of 375 mm. The PET scan of the
same region had an acquisition time of 25 min per bed
position.
Automated quantification method
The core of the automated segmentation method is a fully
convolutional neural network (CNN) (Ian Goodfellow et al.,
2016). For each voxel in the CT image, the network estimates
the probability that this voxel belongs to the prostate gland.
Figure 1 Bland–Altman plot illustrating the
agreement of prostate gland volume measure-
ments (ml) between Radiologist A and B (a),
DL-algorithm and Radiologist A (b), as well
as DL-algorithm and Radiologist B (c) in the
validation group of 43 patients (data from
Table 2). Representation of confidence interval
limits for mean and agreement limits (black
dotted lines) as well as the line of equality
(blue dotted line).
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The voxel values of the CT scan were used as input to the
CNN. The input was split into three separate pipes. Each pipe
processes the image at a different scale, from coarse scale that
is downsampled by a factor of four, to fine scale with no
downsampling. Working on several scales allows for a large
receptive field without excessive memory consumption,
enabling efficient training of the model on a regular graphics
card. Apart from the downsampling, the three pipes are iden-
tically designed with three dilated convolutional layers (Chen
et al., 2018). Before merging the pipes, the two coarse-scale
pipes are upsampled to the full spatial resolution. All convolu-
tional layers use rectified linear units (Ian Goodfellow et al.,
2016) as activation functions except the last one, which uses
softmax to produce output probabilities that sum to one. The
network contains roughly 1 million weights that have to be
learnt from the training data. The goal of this process is to
make the model output on the training set as similar as possi-
ble to the manual segmentations (Ian Goodfellow et al.,
2016). As evaluating this loss function is extremely time-con-
suming, the minimization is performed using stochastic gradi-
ent descent; a random sample is selected and the gradient of
the loss for this specific example is computed, then a small
step in the negative direction of this gradient is taken.
Postprocessing
The raw segmentation from the CNN is not always perfect. Spo-
radically, background voxels are classified as prostate gland. To
address this problem only the largest connected component
from the CNN prostate segmentation is kept. A similar problem
is that isolated voxels inside the prostate gland might be classi-
fied as background. This is addressed by performing morpho-
logical hole filling on the prostate gland mask.
Training
The deep learning-based method was trained to segment the
prostate gland using CT scans in which the prostate gland was
segmented manually by one radiologist (Radiologist A) with
six years of experience. Manual segmentation was performed
using a cloud-based segmentation tool (RECOMIA, https://
www.recomia.org) by the radiologist. The tool is voxel based
allowing the observer to mark prostate gland voxels in the
three-dimensional CT volume and in any of the three planes
(transaxial, coronal or sagittal).
Validation
After training, the segmentation method was applied to the vali-
dation group. The prostate glands were automatically seg-
mented in the CT scans. Voxels in the co-registered PET images
above an SUV of 265, as proposed by Reske et al. (2006) and
corresponding to the prostate gland as defined in the CT
images, were defined as abnormal. The following five auto-
mated PET-measures were calculated: maximal SUV within the
prostate gland (SUVmax); average SUV for voxels with
SUV > 265 (SUVmean); volume of voxels with SUV > 265 in
ml (VOLUME); fraction of VOLUME related to the whole vol-
ume of the prostate gland (FRACTION); and product
SUVmean 9 VOLUME reflecting the total lesion uptake (TLU).
Validation methods
Validation of prostate volume
The prostate glands of the 45 patients in the validation group
were automatically segmented in the CT scans by the algo-
rithm. Further, two observers with a minimum of six years of
experience performed individual manual segmentations of the
prostates of the same material. Thereafter, the automated and
manual segmentations were compared with each other.
Validation of PET uptake
An experienced radiologist and a nuclear medicine physician
independently evaluated the abnormal PET uptake in the pros-
tate gland of the validation group. The same cloud-based seg-
mentation tool as in the training group (https://www.rec
omia.org) was used. Automated TLU measurements were
compared with the manual evaluations of the physicians.
Clinical validation
The prognostic value of automated quantification was assessed
by studying the association between the PET/CT measurements
Table 2 Mean difference in prostate volume (ml) between the algo-








DLa-Rad.Ab 10 (16 to 4) 278 482
DL-Rad.Bc 055 (7 to 6) 39 40






Table 3 Sørensen-Dice index (SDI) showing the agreement between
the automated and the manual segmentations of Radiologist A and
Radiologist B (n = 43).
Median 25th percentile 75th percentile
DL-baseda vs Rad. A 083 076 084
DL-based vs Rad. B 080 074 084
Rad. A vs Rad. B 086 083 089
aDL-deep learning.
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and the common clinical measures, that is age, Gleason score
and PSA with overall survival in the validation group.
Statistical analysis
The Sørensen-Dice index (SDI) was used to evaluate the
agreement between automated and manual segmentations by
analysis of number of overlapping voxels. The SDI is defined
as twice the number of overlapping voxels divided by the
sum of the total amount of voxels classified as prostate in
both segmentations. Coefficient values range between 0 and
1, with 1 reflecting perfect agreement (D, 1999). The agree-
ment between the automated measurements and the obser-
vers as well as agreement between observers were further
Figure 2 Bland–Altman plot illustrating the
agreement of total lesion uptake (TLU) mea-
surements between the nuclear medicine
(NM) physician and the Radiologist B (a),
DL-algorithm and NM physician (b), as well
as DL-algorithm and the Radiologist B (c) in
the validation group of 43 patients (data from
Table 4). Representation of confidence interval
limits for mean and agreement limits (black
dotted lines) as well as the line of equality
(blue dotted line).
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evaluated using Bland–Altman analysis and linear regression
analysis. Associations between automated PET/CT measure-
ments, age, PSA, Gleason score and overall survival were
investigated using a univariate Cox proportional hazards
regression model. Overall survival was calculated from the
date of PET/CT scan. Hazard ratios (HR) and 95% confi-
dence intervals (CI) were estimated. The level of significance
was set at 005. The R statistical computing environment




The algorithm failed in two patients with hip prostheses caus-
ing beam hardening. Both examinations were excluded and
results from the remaining 43 patients are shown in Table 1.
The median prostate gland volume was 71 ml (range 17–
118) with automated segmentation, corresponding to 65 ml
(range 9–184) and 80 ml (range 9–176), with manual seg-
mentation by the two radiologists (Fig. 1a-c). The mean dif-
ference regarding volume was 10 ml between the radiologists,
and 10 ml and 055 ml between the algorithm and Radi-
ologist A and B, respectively (Table 2).
The automatically derived volume was in between the two
manually determined volumes in 14 of 43 (33%) patients.
The overlap between automated and the two manual prostate
gland segmentations showed SDIs of 078 and 079, respec-
tively. The analysis of inter-observer agreement for the two
radiologists showed an SDI of 084 (Table 3). Significant cor-
relation was found between difference and mean of prostate
volume of the automated and the manual volume measure-
ments (P<0001). The agreement between the algorithm and
the observers was dependent on prostate volume, with the
algorithm overestimating small glands and underestimating
large glands.
Lesion uptake
Median TLU was 105 (range 0–421) by the algorithm-based
method. The two readers obtained a median TLU of 62 (range
0–572) and 126 (range 1–620), respectively (Fig. 2a-c). The
mean difference regarding total lesion uptake was 59
between the two observers, corresponding to 29 and 30
between the algorithm and the nuclear medicine physician
and radiologist, respectively (Table 4). The automated TLU
values were in between the two manually obtained values in
19 of 43 (44%) patients. Regression analysis showed no sig-
nificant correlation between difference and mean of the lesion
uptake of the nuclear medicine physician and the algorithm
(P = 007), whereas the manual measurements of the Radiol-
ogist A were generally higher than their corresponding mea-
surements made by the algorithm and the nuclear medicine
physician.
Analysis of survival
In the univariate Cox analysis, three of the automatically
derived volumetric measurements (VOLUME, FRACTION and
TLU), all measures by the nuclear medicine physician as well
Table 5 Univariate survival analysis demonstrating the association
between PET/CT measurements, age, PSA, as well as Gleason score







SUVmaxb 103 095–111 051
SUVmeanc 113 090–142 030
VOLUME (ml)d 102 1003–1036 002
FRACTION (%)e 102 1003–1038 002







SUVmaxb 113 1016–1263 003
SUVmeanc 138 1019–1862 004
VOLUME (ml)d 101 1001–1024 003
TLUf 1002 10002–1005 003
Radiologist Hazard ratio 95% CI P-value
SUVmaxb 104 0973–1122 023
SUVmeanc 108 0875–1345 046
VOLUME (ml)d 101 1003–1024 001
FRACTION (%)e 10004 0993–1008 091
TLUf 1002 10004–10046 002
Clinical data Hazard ratio 95% CI P-value
Age 104 099–109 006
PSA (log)a 139 087–223 017
Gleason score 115 088–152 030
aProstate-specific antigen (ng/ml) logarithmic.
bMaximal SUV within the prostate gland.
cAverage SUV for voxels with SUV > 265.
dVolume of prostate gland voxels with SUV > 265.
eFraction of VOLUME related to the whole volume of the prostate
gland.
fProduct SUVmean 9 VOLUME reflecting the total lesion uptake.
Table 4 Mean difference of total lesion uptake between the DL-









DLa- Radiologist B 30 (53 to 7) 1175 177
DL-NMb physician 29 (12 to 46) 1364 785
NM physician-
Radiologist B
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as VOLUME and TLU by the radiologist were significantly
associated with overall survival. The other PET/CT measure-
ments, age, PSA (logarithmic) and Gleason score, were not.
The results are shown in Table 5, where hazard ratio accounts
for one unit change of each of the automated variables. Fig-
ure 3 shows the PET/CT scans from two study patients and
their respective automatically based measurements.
Discussion
Automatically based estimates of 18F-choline uptake in the
prostate gland reflecting lesion volume and total lesion uptake
were significantly associated with overall survival contrary to
age, PSA and Gleason score. They were similar to values
obtained manually by radiologists, but much faster. Moreover,
they provide measures of cancer reflecting metabolically active
cells. Thus, these measurements may be clinically more rele-
vant than SUVmax or SUVpeak representing only minute vol-
umes of cancerous tissue with high activity, whereas the
entire volume of cancer and its overall activity is a conceptu-
ally more truthful measure of the cancerous burden (Basu
et al., 2014; Boellaard et al., 2015; Ziai et al., 2016).
Volumetric analysis by manual processing is not standard-
ized and is a time-consuming clinical application. The algo-
rithm provides automated and clinically relevant measures
within seconds that may substitute or significantly improve
today’s mainly visual assessment of CT, MRI, PET/CT and
PET/MRI. Thus, it may significantly increase the diagnostic
accuracy and precision of PET/CT imaging. In prostate cancer,
it may become as important as PSA and Gleason score for
identifying high- and low-risk patients. Our approach was
trained with scans from one institution and validated by scans
from another, a circumstance indicating that the algorithm is
applicable in other settings than where it was trained. Thus, it
could be speculated that if properly trained, the algorithm
could work with other tracers and other scanners.
Limitations
The algorithm overestimated the volume of small glands and
underestimated large glands. This could at least partly be
explained by the selection of cases to the training group. Train-
ing of automated-networks depends on large data sets as well as
on different anatomical conditions in each patient. Larger train-
ing groups with both normal and pathological prostate glands
are likely to improve the performance of the algorithm. A fixed
threshold (SUV > 265) to define abnormal uptake of 18F-cho-
line was used. Other fixed thresholds and other ways of defin-
ing the most relevant borders of abnormal uptake should be
considered in future studies (Schaefferkoetter et al., 2017).
The value of 18F-choline PET is still debatable. Some studies
highlight its application in case of biochemical recurrence at
high PSA levels (>2 ng/ml) and in monitoring of therapy
response (Ceci et al., 2016; Evangelista et al., 2016). Other
recent studies have analysed the higher accuracy of 68Ga-
PSMA in detecting prostate cancer (Morigi et al., 2015; Evan-
gelista et al., 2016; Eapen et al., 2018). Hence, the clinical
application of the latter has increased over the past few years.
Yet, a recent study showed a 205% positive detection rate of
11C-choline PET/CT in prostate cancer patients with biochemi-
cal failure after radical prostatectomy and PSA < 1 ng/ml
(Giovacchini et al., 2019). More specific prostate cancer tracers
targeting primarily prostate-specific membrane antigen and
with higher positive detection rate contends for precedence in
future studies. However, until such tracers become more
broadly available, radiolabeled choline could still be a valuable
(a) (b)
(c) (d)
Figure 3 18F-choline PET/CT scans of two study patients, one aged 68 with survival time 3 years and 8 months (a, b) and another aged 72 with
survival time 1 year and 3 months (c, d). Upper panels (a, c) show fused PET and CT images, lower panels (b, d) are CT images with automated
segmentation of the prostate gland (yellow) and demonstration (red) of prostate gland cancer obtained from the corresponding PET scan using
SUV > 265 as cut-off. The longer living patient (a, b) had higher PSA (1230 vs 102) and Gleason score (4 + 3 vs 3 + 4), but lower VOLUME
(2 vs 38 ml), FRACTION (7% vs 76%); and TLU (7 vs 236) than the shorter living patient (c, d).
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option. Further, the extensive clinical use of radiolabeled cho-
line PET for many years has the advantage of a long-term fol-
low-up of prostate cancer patients. Although 18F-choline is
not an ideal prostate cancer tracer (Evangelista et al., 2016), it
was used in this study because of the fund of validated scans
available.
Further, the presence of skeletal metastases makes a worse
prognosis itself. Yet, the main purpose of this study was to
demonstrate the feasibility of the algorithm and investigate
its association with overall survival in this patient category,
aware of the association between cancer spread and sur-
vival.
In conclusion, automated, volume-based measures of 18F-
choline uptake in the prostate gland could be obtained by the
algorithm and showed good agreement with the manually
assessed measurements. In addition, the automated PET/CT
biomarkers were significantly associated with overall survival
despite suboptimal tracer characteristics. The algorithm is now
open for investigation in other cancers and with other tracers.
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